Results 31 to 40 of about 7,380 (205)
Amodiaquine and malaria prophylaxis
Parasitology Today, 1986 Abstract In 1985 the WHO and the United States Centers for Disease Control recommended that amodiaquine (400 mg weekly) could be used as a first-line malaria prophylactic in areas of the world with chloroquine resistance. Recently both the WHO and the CDC have withdrawn this recommendation.
Peto, T. E.A., Gilks, C. F.
openaire +3 more sources
Biomédica: revista del Instituto Nacional de Salud, 2003 La resistencia a los antimaláricos es una de las causas del aumento de casos de malaria en el mundo. Desde el año 2000, el tratamiento de malaria no complicada por Plasmodium falciparum en Colombia ha sido la combinación de amodiaquina (AQ) y sulfadoxina/
Iveth J. González +3 more
doaj +1 more source
Effects of immunization and checkpoint inhibition on amodiaquine-induced liver injury
Journal of Immunotoxicology, 2017 If idiosyncratic drug-induced liver injury (IDILI) is immune-mediated, it is possible that an individual’s prior exposure to antigens may affect their susceptibility to IDILI.
Alastair Mak +2 more
doaj +1 more source
Revista da Sociedade Brasileira de Medicina Tropical, 2012 INTRODUCTION: In Colombia, there are no published studies for the treatment of uncomplicated Plasmodium falciparum malaria comparing artemisinin combination therapies.
Fernando De la Hoz Restrepo +4 more
doaj +1 more source
In silico identification of clinically approved medicines against the main protease of SARS-CoV-2, causative agent of covid-19 [PDF]
arXiv, 2020 The COVID-19 pandemic triggered by SARS-CoV-2 is a worldwide health disaster. Main protease is an attractive drug target among coronaviruses, due to its vital role in processing the polyproteins that are translated from the viral RNA. There is presently no exact drug or treatment for this diseases caused by SARS-CoV-2.
arxiv
Immunization with amodiaquine-modified hepatic proteins prevents amodiaquine-induced liver injury [PDF]
Journal of Immunotoxicology, 2014 Amodiaquine (AQ) has been reported to cause severe idiosyncratic drug-induced liver injury (IDILI) in humans. There is evidence that AQ-induced idiosyncratic drug reactions are immune mediated, but their exact mechanism is not fully understood. AQ is oxidized to a reactive quinoneimine metabolite, and it has been suggested that covalent binding of this
Alastair Mak, Jack Uetrecht
openaire +3 more sources
Opportunities and Challenges of Population Pharmacogenomics
Annals of Human Genetics, EarlyView.ABSTRACT Pharmacological responses can vary significantly among patients from different ethnogeographic backgrounds. This variability can, at least in part, be attributed to population‐specific genetic patterns in genes involved in drug absorption, distribution, metabolism, and excretion, as well as in genes associated with drug‐induced toxicity ...
Yitian Zhou +3 more
wiley +1 more source
Organoid Models to Study Human Infectious Diseases
Cell Proliferation, EarlyView.Our manuscript reviews the role of organoids as models for studying human infectious diseases, highlighting their irreplaceable contributions to drug testing and vaccine development for significant infectious diseases including HIV, ZIKV, SARS‐CoV‐2 and MPXV.
Sijing Zhu +4 more
wiley +1 more source
Wellcome Open Research, 2018 Background: The human malaria parasite Plasmodium falciparum has evolved drug evasion mechanisms to all available antimalarials. The combination of amodiaquine-artesunate is among the drug of choice for treatment of uncomplicated malaria.
Loise Ndung'u +6 more
doaj +1 more source
Synthesis of New 4-Aminoquinolines and Evaluation of Their In Vitro Activity against Chloroquine-Sensitive and Chloroquine-Resistant Plasmodium falciparum. [PDF]
PLoS ONE, 2015 The efficacy of chloroquine, once the drug of choice in the fight against Plasmodium falciparum, is now severely limited due to widespread resistance.
Chandima S K Rajapakse +7 more
doaj +1 more source